The estimated Net Worth of Christopher Lewis Stone is at least $1.47 milliard dollars as of 16 December 2020. Mr. Stone owns over 200,000 units of PDL Biopharma Inc stock worth over $1,462,445,754 and over the last 16 years he sold PDLI stock worth over $512,000. In addition, he makes $2,452,620 as Vice President, General Counsel et Secretary at PDL Biopharma Inc.
Christopher has made over 1 trades of the PDL Biopharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 200,000 units of PDLI stock worth $512,000 on 16 December 2020.
The largest trade he's ever made was selling 200,000 units of PDL Biopharma Inc stock on 16 December 2020 worth over $512,000. On average, Christopher trades about 10,526 units every 0 days since 2009. As of 16 December 2020 he still owns at least 405,559 units of PDL Biopharma Inc stock.
You can see the complete history of Mr. Stone stock trades at the bottom of the page.
Christopher Lewis Stone, J.D. is Vice President, General Counsel, Secretary of the Company. He brings more than 30 years of legal experience to the role. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection and licensing. Prior to that time, he was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company that was acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications, and managed multiple litigation and interference proceedings and numerous European patent oppositions. Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar (company counsel) and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.
As the Vice President, General Counsel et Secretary of PDL Biopharma Inc, the total compensation of Christopher Stone at PDL Biopharma Inc is $2,452,620. There are 1 executives at PDL Biopharma Inc getting paid more, with Dominique Monnet having the highest compensation of $6,701,000.
Christopher Stone is 55, he's been the Vice President, General Counsel et Secretary of PDL Biopharma Inc since 2009. There are 5 older and 2 younger executives at PDL Biopharma Inc. The oldest executive at PDL Biopharma Inc is John McLaughlin, 68, who is the Director.
Christopher's mailing address filed with the SEC is C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD., INCLINE VILLAGE, NV, 89451.
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain et Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
PDL Biopharma Inc executives and other stock owners filed with the SEC include: